Mouse VEGFR1/Flt-1 Antibody

Catalog #: AF471
30 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF471
AF471-SP

Request a Quote Bulk Orders

Cell Proliferation Induced by VEGF164and Neutralization by Mouse VEGFR1/Flt‑1 Antibody.

1 Image

Product Details

Citations (30)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse VEGFR1/Flt-1 Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse VEGFR1/Flt-1 in ELISAs and Western blots.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse VEGFR1/Flt-1
Ser27-Glu759
Accession # P35969

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Mouse VEGFR1/Flt‑1 Fc Chimera (Catalog # 471-F1)

Flow Cytometry

2.5 µg/10⁶ cells

bEnd.3 mouse endothelioma cell line

Blockade of Receptor-ligand Interaction

In a functional ELISA, 1-4 µg/mL of this antibody will block 50% of the binding of 10 ng/mL of Recombinant Mouse PlGF-2 (Catalog # 465-PL) to immobilized Recombinant Mouse VEGFR1/Flt-1 Fc Chimera (Catalog # 471-F1) coated at 1 µg/mL (100 µL/well). At 50 μg/mL, this antibody will block >90% of the binding.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Mouse VEGFR1/Flt-1 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

0.2-0.8 µg/mL

Use in combination with:

Detection Reagent: Mouse VEGFR1/Flt-1 Biotinylated Antibody (Catalog # BAF471)

Standard: Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF (Catalog # 471-F1)

Neutralization

Measured by its ability to neutralize VEGF₁₆₄-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND₅₀) is typically 2-8 µg/mL in the presence of 5 ng/mL Recombinant Mouse VEGF₁₆₄.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by VEGF₁₆₄and Neutralization by Mouse VEGFR1/Flt‑1 Antibody. Recombinant Mouse VEGF₁₆₄ 493-MV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse VEGF₁₆₄(5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGFR1/Flt-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF471). The ND₅₀ is typically 2-8 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR1/Flt-1

VEGFR1 is one of the five receptor tyrosine kinases (RTKs) (VEGFR1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis.

Full length mouse VEGFR1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGFR1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGFR1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGFR1/Fc chimera binds VEGF and PlGF with high affinity and is a potent VEGF antagonist.

References

He, Y. et al. (1999) Molecular Endocrinology 13:537.
Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.

Long Name

Vascular Endothelial Growth Factor Receptor 1

Entrez Gene IDs

2321 (Human); 14254 (Mouse)

Alternate Names

EC 2.7.10; EC 2.7.10.1; FLT; FLT1; Flt-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor); FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGF R1; VEGFR1; VEGFR-1

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Mouse VEGFR1/Flt-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

30 Citations: Showing 1 - 10
Filter your results:

Filter by:

The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition
Authors: CCL van Aanhol, A Koudijs, KL Dijkstra, R Wolterbeek, JA Bruijn, C van Kooten, HJ Baelde
International Journal of Molecular Sciences, 2022;23(17):.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC
BMP9 signaling promotes the normalization of tumor blood vessels
Authors: C Viallard, C Audiger, N Popovic, N Akla, K Lanthier, I Legault-Na, H Melichar, S Costantino, S Lesage, B Larrivée
Oncogene, 2020;0(0):.
Species: Transgenic Mouse
Sample Types: Cell Lysates
Applications: Western Blot
Injured Axons Instruct Schwann Cells to Build Constricting Actin Spheres to Accelerate Axonal Disintegration
Authors: A Vaquié, A Sauvain, M Duman, G Nocera, B Egger, F Meyenhofer, L Falquet, L Bartesaghi, R Chrast, CM Lamy, S Bang, SR Lee, NL Jeon, S Ruff, C Jacob
Cell Rep, 2019;27(11):3152-3166.e7.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization
Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy
Authors: M Verma, Y Shimizu-Mo, Y Asakura, JP Ennen, J Bosco, Z Zhou, GH Fong, S Josiah, D Keefe, A Asakura
PLoS Genet., 2019;15(12):e1008468.
Species: Mouse
Sample Types: Tissue
Applications: IHC frozen fixed
Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering
Authors: F Zhao, L Zhou, J Liu, Z Xu, W Ping, H Li, L Xu, Z Xu, C Zhou, M Wang, R Jia
J Tissue Eng, 2019;10(0):2041731419891.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization
Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy
Authors: SC Teixeira, DS Lopes, SN Gimenes, TL Teixeira, MS da Silva, RT Brígido, FA da Luz, AA da Silva, MA Silva, PV Florentino, PC Tavares, MA Dos Santos, VM Ávila, MJ Silva, MC Elias, RA Mortara, CV da Silva
Sci Rep, 2017;7(0):44978.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia
Nat Commun, 2016;7(0):13650.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC
Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage.
Authors: Hou, Sheng Ta, Nilchi, Ladan, Li, Xuesheng, Gangaraju, Sandhya, Jiang, Susan X, Aylsworth, Amy, Monette, Robert, Slinn, Jacqueli
Sci Rep, 2015;5(0):7890.
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay
Differential apicobasal VEGF signaling at vascular blood-neural barriers.
Authors: Hudson N, Powner M, Sarker M, Burgoyne T, Campbell M, Ockrim Z, Martinelli R, Futter C, Grant M, Fraser P, Shima D, Greenwood J, Turowski P
Dev Cell, 2014;30(5):541-52.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr
The role of IL-1beta in the early tumor cell-induced angiogenic response.
Authors: Carmi Y, Dotan S, Rider P, Kaplanov I, White M, Baron R, Abutbul S, Huszar M, Dinarello C, Apte R, Voronov E
J Immunol, 2013;190(7):3500-9.

Nonmuscle myosin light-chain kinase mediates microglial migration induced by HIV Tat: involvement of beta1 integrins.
Authors: Yao H, Duan M, Yang L, Buch S
FASEB J, 2013;27(4):1532-48.
Species: Rat
Sample Types: Whole Cells
Applications: Neutralization

Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
Authors: Benedito R, Rocha S, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams R
Nature, 2012;484(7392):110-4.
Species: Mouse
Sample Types: Tissue Homogenates
Applications: Immunoprecipitation

The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy.
Authors: Schreurs MP, Houston EM, May V, Cipolla MJ
FASEB J., 2012;26(1):355-62.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization

Hypoxia-inducible factor-2alpha regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
Authors: Roda JM, Sumner LA, Evans R, Phillips GS, Marsh CB, Eubank TD
J. Immunol., 2011;187(4):1970-6.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.
Authors: Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, Kuppusamy P, Marsh CB
Cancer Res., 2009;69(5):2133-40.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
Authors: Shin JY, Yoon IH, Kim JS, Kim B, Park CG
Cell. Immunol., 2009;256(1):72-8.
Species: Mouse
Sample Types: Whole Cells
Applications: Neutralization

VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.
Authors: Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, Lennartsson J, Zhu C, Qu Y, Fang C, Hua J, Matsuo O, Fong GH, Ding H, Cao Y, Becker KG, Nash A, Heldin CH, Li X
J. Clin. Invest., 2008;118(3):913-23.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

VEGF promotes vascular sympathetic innervation.
Authors: Marko SB, Damon DH
Am. J. Physiol. Heart Circ. Physiol., 2008;294(6):H2646-52.
Species: Rat
Sample Types: Whole Cells
Applications: ICC

alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
Authors: Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
Blood, 2007;111(4):1980-8.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot

Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential.
Authors: Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T
Am. J. Pathol., 2006;169(4):1167-82.
Species: Mouse
Sample Types: Tissue Homogenates
Applications: ELISA Development

Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.
Authors: Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J
J. Clin. Invest., 2006;116(2):422-9.
Species: Mouse
Sample Types: Cell Lysates
Applications: Immunoprecipitation

VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
Nat. Neurosci., 2006;9(3):340-8.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr

Corneal avascularity is due to soluble VEGF receptor-1.
Authors: Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J
Nature, 2006;443(7114):993-7.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Authors: Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG
Cancer Res., 2006;66(22):10919-28.
Species: Mouse
Sample Types: Whole Cells
Applications: Neutralization

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
Authors: Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP
J. Immunol., 2005;174(1):215-22.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot

Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue.
Authors: Gudehithlu KP, Ahmed N, Wu H, Litbarg NO, Garber SL, Arruda JA, Dunea G, Singh AK
J. Lab. Clin. Med., 2005;145(4):194-203.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC-P

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
Authors: Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
Invest. Ophthalmol. Vis. Sci., 2004;45(2):368-74.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

Vascular endothelial growth factor-B promotes in vivo angiogenesis.
Authors: Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI
Circ. Res., 2003;93(2):114-23.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
Authors: Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C
J. Cell Biol., 2003;161(6):1163-77.
Species: Rat
Sample Types: In Vivo
Applications: Neutralization

Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Authors: Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Uematsu T
Blood, 2002;100(7):2487-93.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization